[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465142":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":43,"centralContacts":47,"locations":52,"responsibleParty":68,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":85,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":97,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14,18,22,26,29,33],{"label":9,"type":10,"description":11,"interventionNames":12},"Viral infection",null,"Viral infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree",[13],"Diagnostic Test: Biomarker blood draw and saliva collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Bacterial infection","Bacterial infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +\u002F- 6 hours from symptom onset (if available); and c) 48 hours +\u002F- 6 hours from symptom onset (if available).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Viral-Viral co-infection","Viral-viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +\u002F- 6 hours from symptom onset (if available); and c) 48 hours +\u002F- 6 hours from symptom onset (if available).",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Bacterial-Viral co-infection","Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +\u002F- 6 hours from symptom onset (if available); and c) 48 hours +\u002F- 6 hours from symptom onset (if available).",[13],{"label":27,"type":10,"description":24,"interventionNames":28},"Fungal-Mycobacterium co-infection",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"Infection of uncertain origin","Infection of uncertain origin subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +\u002F- 6 hours from symptom onset (if available); and c) 48 hours +\u002F- 6 hours from symptom onset (if available).",[13],{"label":34,"type":10,"description":35,"interventionNames":36},"Control Subjects","Control group subjects, if they agree, will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms (if applicable); and if they agree, a further two samples at b) 24 hours +\u002F- 6 hours from symptom onset (if applicable); and c) 48 hours +\u002F- 6 hours from symptom onset (if applicable).",[13],[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":10},"DIAGNOSTIC_TEST","Biomarker blood draw and saliva collection","Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)",[15,23,34,27,30,9,19],[44],{"name":45,"affiliation":5,"role":46},"Timothy H Rainer, MD","PRINCIPAL_INVESTIGATOR",[48],{"name":45,"role":49,"phone":50,"phoneExt":10,"email":51},"CONTACT","+852 39176846","thrainer@hku.hk",[53],{"facility":54,"status":55,"city":56,"state":10,"zip":10,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Hong Kong University","RECRUITING","Hong Kong","China","CN",{"type":60,"coordinates":61},"Point",[62,63],114.17469,22.27832,{"lat":63,"lon":62},[66],{"name":45,"role":49,"phone":67,"phoneExt":10,"email":51},"852 39176846",{"type":46,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prof. Timothy Hudson RAINER","Professor of Department of Emergency Medicine","100465142","emergency-pwas-in-respiratory-infectious-disease-100465142",false,"NCT05336851","Emergency PWAS in Respiratory Infectious Disease","Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)","Inclusion Criteria:\n\nPatients eligible for enrolment include:\n\nWith reference to previous inclusion criteria are:\n\n* Adults ≥18 years of age; AND\n* Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\\*; AND\n* Informed consent.\n\nNote: scaRID is defined according to ALL three criteria:\n\n1. Community acquired (not hospitalised for \\\u003C28 days); AND\n2. Acute infection (defined as symptom onset \\\u003C8 days and any ONE of reported fever or chills or aural temperature \\>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND\n3. Probable respiratory infection - According to any ONE of:\n\n   1. new cough or new sputum production or\n   2. chest pain or\n   3. dyspnoea or\n   4. tachypnoea or\n   5. abnormal lung examination or\n   6. respiratory failure; or\n   7. physician's judgment (presenting with systemic or gastrointestinal symptoms).\n\nControl subjects will be drawn from two groups:\n\n* The worried well - adult patients with a National Early Warning Score (NEWS) \\\u003C3 and a temperature \\\u003C37.5°C.\n* Relatives or accompanying friends with no acute illness.\n\nExclusion Criteria:\n\n* Refusal of consent;\n* Recent hospitalisation (\\\u003C28 days);\n* Enrolled in another clinical trial\n* Cellulitis;\n* Skin or orthopaedic infections;\n* Urinary tract infection;\n* Acute abdominal sepsis;\n* Sexual transmitted disease;\n* Human immunodeficiency virus (HIV) infection;\n* Immunocompromised\u002Fpotential neutropenic fever;\n* Solid organ or haematopoietic stem-cell transplant within the previous 90 days;\n* Active graft-versus-host disease or bronchiolitis obliterans;\n* Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;\n* Stroke;\n* Toxidrome;\n* Non-organic acute psychosis.",true,"ALL","18 Years","100 Years",{"count":83,"type":84},2000,"ESTIMATED","1 Year","OBSERVATIONAL","Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).\n\nPhase 1\n\n1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2\n2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics",[89,90,91,92,93,94,95,96],"Viral Infections","Bacterial Infections","Fungal Infections","Mixed Infection","Mycobacterium Infection","Infection of Uncertain Aetiology","Pneumonia","Sepsis",[98,99,100,101,102],"Biobank","Diagnostics and Prognostics","Emergency Medicine","Multiomics and Panoromics","Respiratory Infectious Disease","2026-05-07",{"date":105,"type":106},"2026-05-12","ACTUAL",{"date":108,"type":106},"2023-04-11",{"date":110,"type":84},"2028-05-01",{"name":5,"class":6},1]